132 related articles for article (PubMed ID: 19222997)
1. Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury.
Luo Q; Wang Y; Feng D; Xu Y; Xu L
Eur J Pharmacol; 2009 Apr; 607(1-3):226-33. PubMed ID: 19222997
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.
Ishizaki K; Iwaki T; Kinoshita S; Koyama M; Fukunari A; Tanaka H; Tsurufuji M; Sakata K; Maeda Y; Imada T; Chiba K
Eur J Pharmacol; 2008 Jan; 578(1):57-64. PubMed ID: 17888421
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate-protein kinase a pathway.
Ji H; Zhang Y; Liu Y; Shen XD; Gao F; Nguyen TT; Busuttil RW; Waschek JA; Kupiec-Weglinski JW
Liver Transpl; 2013 Sep; 19(9):945-56. PubMed ID: 23744729
[TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin-3-gallate protects mice from concanavalin A-induced hepatitis through suppressing immune-mediated liver injury.
Wang Y; Mei Y; Feng D; Xu L
Clin Exp Immunol; 2006 Sep; 145(3):485-92. PubMed ID: 16907918
[TBL] [Abstract][Full Text] [Related]
5. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
7. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.
Wang Y; Mei Y; Bao S; Xu L
Clin Exp Immunol; 2007 Apr; 148(1):178-87. PubMed ID: 17349016
[TBL] [Abstract][Full Text] [Related]
9. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
[TBL] [Abstract][Full Text] [Related]
10. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice.
Louis H; Le Moine O; Peny MO; Quertinmont E; Fokan D; Goldman M; Devière J
Hepatology; 1997 Jun; 25(6):1382-9. PubMed ID: 9185757
[TBL] [Abstract][Full Text] [Related]
11. CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice.
Zhang H; Gong Q; Li JH; Kong XL; Tian L; Duan LH; Tong J; Song FF; Fang M; Zheng F; Xiong P; Tan Z; Gong FL
Int Immunopharmacol; 2010 Jan; 10(1):79-85. PubMed ID: 19818415
[TBL] [Abstract][Full Text] [Related]
12. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A.
Küsters S; Gantner F; Künstle G; Tiegs G
Gastroenterology; 1996 Aug; 111(2):462-71. PubMed ID: 8690213
[TBL] [Abstract][Full Text] [Related]
13. Baicalin protects mouse from Concanavalin A-induced liver injury through inhibition of cytokine production and hepatocyte apoptosis.
Liu LL; Gong LK; Wang H; Xiao Y; Wu XF; Zhang YH; Xue X; Qi XM; Ren J
Liver Int; 2007 May; 27(4):582-91. PubMed ID: 17403198
[TBL] [Abstract][Full Text] [Related]
14. Effect of diphenyl dimethyl bicarboxylate on concanavalin A-induced liver injury in mice.
Gao M; Zhang J; Liu G
Liver Int; 2005 Aug; 25(4):904-12. PubMed ID: 15998443
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Toll-like receptor 4 with vasoactive intestinal peptide attenuates liver ischemia-reperfusion injury.
Jiang W; Tang W; Geng Q; Xu X
Transplant Proc; 2011 Jun; 43(5):1462-7. PubMed ID: 21693218
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro.
Yang J; Shi QD; Song TB; Feng GF; Zang WJ; Zong CH; Chang L
Peptides; 2013 Apr; 42():105-11. PubMed ID: 23340020
[TBL] [Abstract][Full Text] [Related]
18. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ
Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743
[TBL] [Abstract][Full Text] [Related]
19. [Protective effects of vasoactive intestinal peptide on intestinal lesions induced by endotoxic shock in rat].
Zhang YC; Yang LP; Tang DH; Zhang YM
Zhonghua Er Ke Za Zhi; 2006 May; 44(5):369-73. PubMed ID: 16780716
[TBL] [Abstract][Full Text] [Related]
20. [Effect of ronggan mixture on immunoregulation and hepatocyte apoptosis-related factors in concanavalin A induced acute immunological liver injury mice].
Zhang YQ; Tang XD; Wang FY; Yang B; Liu YL; Guo P; Wang P; Bian LQ; Zhao YP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Nov; 33(11):1500-6. PubMed ID: 24483111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
